|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 394,000.00 KRW | +2.47% |
|
-4.14% | +50.10% |
| Nov. 10 | PharmaResearch Q3 operating profit 62 billion won, up 77% from year earlier | RE |
| Nov. 05 | PharmaResearch Co., Ltd. announces Annual dividend, payable on April 17, 2026 | CI |
| Capitalization | 4,094B 2.77B 2.36B 2.2B 2.07B 3.82B 251B 4.17B 25.73B 9.98B 118B 10.4B 10.18B 432B | P/E ratio 2025 * |
22.5x | P/E ratio 2026 * | 17.2x |
|---|---|---|---|---|---|
| Enterprise value | 3.81B 2.58M 2.2M 2.05M 1.93M 3.55M 234M 3.88M 23.95M 9.29M 110M 9.67M 9.47M 402M | EV / Sales 2025 * |
6.94x | EV / Sales 2026 * | 5.08x |
| Free-Float |
60.63% | Yield 2025 * |
0.34% | Yield 2026 * | 0.47% |
| 1 day | +2.47% | ||
| 1 week | -4.14% | ||
| Current month | -16.17% | ||
| 1 month | -10.45% | ||
| 3 months | -39.66% | ||
| 6 months | -24.38% | ||
| Current year | +50.10% |
| 1 week | 380,000 |  | 404,500 |
| 1 month | 380,000 | | 496,000 |
| Current year | 233,500 | | 713,000 |
| 1 year | 229,500 | | 713,000 |
| 3 years | 65,100 | | 713,000 |
| 5 years | 53,500 | | 713,000 |
| 10 years | 29,700 | | 713,000 |
| Manager | Title | Age | Since |
|---|---|---|---|
Ji-Hoon Sohn
CEO | Chief Executive Officer | 61 | 2025-03-24 |
Chi-Yup Won
CTO | Chief Tech/Sci/R&D Officer | 61 | - |
Rae-Seung Jung
PRN | Corporate Officer/Principal | 37 | 2025-03-24 |
| Director | Title | Age | Since |
|---|---|---|---|
Sang-Soo Jung
CHM | Chairman | 67 | - |
Yu-Jin Jung
BRD | Director/Board Member | 34 | - |
Dong-Cheol Seo
BRD | Director/Board Member | 69 | 2023-03-29 |
| Name | Weight | AuM | Varia. Jan 1. | Investor |
|---|---|---|---|---|
 | 0% | 51 M€ | +4.72% | - |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
| +2.47% | -4.14% | +69.83% | +473.51% | 2.72B | |
| -0.74% | +2.56% | -4.10% | -1.17% | 76.62B | |
| +2.86% | -0.91% | -34.22% | -38.37% | 57.54B | |
| -2.24% | -1.92% | +30.76% | +228.36% | 53.75B | |
| +1.38% | +69.20% | +69.20% | +69.20% | 52.52B | |
| +0.93% | -4.33% | +10.57% | -38.99% | 25.31B | |
| -0.72% | -5.03% | +31.62% | +15.87% | 18.87B | |
| +1.85% | -8.93% | +123.04% | +164.19% | 18.42B | |
| -4.52% | -16.57% | +40.58% | +954.81% | 16.49B | |
| +1.46% | +0.52% | +159.32% | +745.33% | 14.27B | |
| Average | +0.27% | -2.23% | +49.66% | +257.27% | 33.65B | |
| Weighted average by Cap. | +0.17% | -0.73% | +27.54% | +129.61% |
| 2025 * | 2026 * | |
|---|---|---|
| Net sales | 549B 372M 317M 296M 278M 512M 33.65B 560M 3.45B 1.34B 15.86B 1.39B 1.36B 57.88B | 713B 483M 411M 384M 362M 666M 43.74B 727M 4.49B 1.74B 20.62B 1.81B 1.77B 75.22B |
| Net income | 187B 127M 108M 101M 94.96M 175M 11.49B 191M 1.18B 457M 5.42B 476M 466M 19.76B | 242B 164M 140M 130M 123M 226M 14.85B 247M 1.52B 591M 7B 615M 602M 25.54B |
| Net Debt | -284B -192M -164M -153M -144M -265M -17.42B -290M -1.79B -693M -8.21B -722M -706M -29.95B | -466B -316M -269M -251M -236M -435M -28.59B -475M -2.93B -1.14B -13.47B -1.18B -1.16B -49.16B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 25-12-12 | 394,000.00 ₩ | +2.47% | 94,621 |
| 25-12-11 | 384,500.00 ₩ | -0.39% | 164,106 |
| 25-12-10 | 386,000.00 ₩ | -0.77% | 104,807 |
| 25-12-09 | 389,000.00 ₩ | -0.89% | 106,754 |
| 25-12-08 | 392,500.00 ₩ | -2.24% | 129,223 |
End-of-day quote Korea S.E., December 11, 2025
More quotes
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- A214450 Stock
Select your edition
All financial news and data tailored to specific country editions
